RU2017112299A - METHOD FOR PRODUCING AROMATIC HETEROCYCLIC COMPOUND USED AS JAK1 SELECTIVE KINASE INHIBITOR AND USING AROMATIC HETEROCYCLIC COMPOUND - Google Patents
METHOD FOR PRODUCING AROMATIC HETEROCYCLIC COMPOUND USED AS JAK1 SELECTIVE KINASE INHIBITOR AND USING AROMATIC HETEROCYCLIC COMPOUND Download PDFInfo
- Publication number
- RU2017112299A RU2017112299A RU2017112299A RU2017112299A RU2017112299A RU 2017112299 A RU2017112299 A RU 2017112299A RU 2017112299 A RU2017112299 A RU 2017112299A RU 2017112299 A RU2017112299 A RU 2017112299A RU 2017112299 A RU2017112299 A RU 2017112299A
- Authority
- RU
- Russia
- Prior art keywords
- fluoro
- phenylamino
- propyl
- amino
- methylacrylamido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Claims (145)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410471468.9 | 2014-09-16 | ||
CN201410471468.9A CN105399685B (en) | 2014-09-16 | 2014-09-16 | The alternatively preparation method and applications of the heteroaromatic compounds of property JAK3 and/or JAK1 kinase inhibitors |
PCT/CN2015/089499 WO2016041472A1 (en) | 2014-09-16 | 2015-09-14 | Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017112299A3 RU2017112299A3 (en) | 2018-10-17 |
RU2017112299A true RU2017112299A (en) | 2018-10-17 |
RU2671195C2 RU2671195C2 (en) | 2018-10-30 |
Family
ID=55465491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017112299A RU2671195C2 (en) | 2014-09-16 | 2015-09-14 | Method for obtaining aromatic heterocyclic compound used as selective inhibitor of kinase jak1 and application thereof |
Country Status (22)
Country | Link |
---|---|
US (1) | US10011571B2 (en) |
EP (1) | EP3196194B1 (en) |
JP (1) | JP6516305B2 (en) |
KR (1) | KR101971887B1 (en) |
CN (1) | CN105399685B (en) |
AU (1) | AU2015317937B2 (en) |
BR (1) | BR112017005113B1 (en) |
CA (1) | CA2982881C (en) |
CY (1) | CY1122423T1 (en) |
DK (1) | DK3196194T3 (en) |
ES (1) | ES2754403T3 (en) |
HK (1) | HK1220975A1 (en) |
HR (1) | HRP20191734T1 (en) |
HU (1) | HUE045899T2 (en) |
LT (1) | LT3196194T (en) |
PL (1) | PL3196194T3 (en) |
PT (1) | PT3196194T (en) |
RS (1) | RS59467B1 (en) |
RU (1) | RU2671195C2 (en) |
SI (1) | SI3196194T1 (en) |
TW (1) | TWI570109B (en) |
WO (1) | WO2016041472A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022001295A (en) * | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
TW202120092A (en) * | 2019-11-08 | 2021-06-01 | 大陸商深圳微芯生物科技股份有限公司 | Use of compound in preventing or treating graft versus host disease |
KR20220113967A (en) * | 2019-11-26 | 2022-08-17 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | Compositions containing aromatic heterocyclic compounds in amorphous form, and methods for their preparation and uses thereof |
CN111297866B (en) * | 2020-03-09 | 2021-04-02 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof |
WO2022222948A1 (en) | 2021-04-22 | 2022-10-27 | 深圳微芯生物科技股份有限公司 | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ539823A (en) | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
CN101421250A (en) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
JP5161233B2 (en) * | 2006-10-19 | 2013-03-13 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-pyrimidinamine derivatives as inhibitors of JAK kinase for the treatment of autoimmune diseases |
WO2008092199A1 (en) * | 2007-01-31 | 2008-08-07 | Cytopia Research Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
DK2361248T3 (en) * | 2008-06-27 | 2019-01-14 | Celgene Car Llc | Heteroberl compounds and uses thereof |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
CN101906076B (en) * | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | Naphthaline amide derivative serving as protein kinase inhibitor and histone deacetylase inhibitor and preparation method and application thereof |
CN103073508B (en) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | The method of inhibitors of kinases and treatment relevant disease |
CN104109127B (en) * | 2013-04-19 | 2019-11-05 | 北京大学深圳研究生院 | Kinase inhibitor and the method for treating related disease |
-
2014
- 2014-09-16 CN CN201410471468.9A patent/CN105399685B/en active Active
-
2015
- 2015-09-14 HU HUE15842179A patent/HUE045899T2/en unknown
- 2015-09-14 PT PT158421792T patent/PT3196194T/en unknown
- 2015-09-14 ES ES15842179T patent/ES2754403T3/en active Active
- 2015-09-14 JP JP2017533675A patent/JP6516305B2/en active Active
- 2015-09-14 DK DK15842179T patent/DK3196194T3/en active
- 2015-09-14 PL PL15842179T patent/PL3196194T3/en unknown
- 2015-09-14 RU RU2017112299A patent/RU2671195C2/en active
- 2015-09-14 SI SI201530965T patent/SI3196194T1/en unknown
- 2015-09-14 EP EP15842179.2A patent/EP3196194B1/en active Active
- 2015-09-14 US US15/510,758 patent/US10011571B2/en active Active
- 2015-09-14 RS RSP20191336 patent/RS59467B1/en unknown
- 2015-09-14 LT LTEP15842179.2T patent/LT3196194T/en unknown
- 2015-09-14 KR KR1020177009942A patent/KR101971887B1/en active IP Right Grant
- 2015-09-14 AU AU2015317937A patent/AU2015317937B2/en active Active
- 2015-09-14 BR BR112017005113-3A patent/BR112017005113B1/en active IP Right Grant
- 2015-09-14 CA CA2982881A patent/CA2982881C/en active Active
- 2015-09-14 WO PCT/CN2015/089499 patent/WO2016041472A1/en active Application Filing
- 2015-09-15 TW TW104130419A patent/TWI570109B/en active
-
2016
- 2016-08-01 HK HK16109126.0A patent/HK1220975A1/en unknown
-
2019
- 2019-09-25 HR HRP20191734 patent/HRP20191734T1/en unknown
- 2019-10-25 CY CY20191101116T patent/CY1122423T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT3196194T (en) | 2019-11-18 |
RU2017112299A3 (en) | 2018-10-17 |
CA2982881C (en) | 2020-02-25 |
HRP20191734T1 (en) | 2019-12-13 |
EP3196194B1 (en) | 2019-08-07 |
US10011571B2 (en) | 2018-07-03 |
WO2016041472A1 (en) | 2016-03-24 |
KR101971887B1 (en) | 2019-04-25 |
CN105399685A (en) | 2016-03-16 |
JP2017527625A (en) | 2017-09-21 |
JP6516305B2 (en) | 2019-05-22 |
AU2015317937A1 (en) | 2017-04-27 |
RU2671195C2 (en) | 2018-10-30 |
EP3196194A1 (en) | 2017-07-26 |
US20170253566A1 (en) | 2017-09-07 |
SI3196194T1 (en) | 2019-12-31 |
CN105399685B (en) | 2018-05-22 |
TWI570109B (en) | 2017-02-11 |
BR112017005113B1 (en) | 2023-02-14 |
BR112017005113A2 (en) | 2018-01-23 |
HK1220975A1 (en) | 2017-05-19 |
DK3196194T3 (en) | 2019-10-28 |
RS59467B1 (en) | 2019-11-29 |
ES2754403T3 (en) | 2020-04-17 |
PL3196194T3 (en) | 2020-01-31 |
HUE045899T2 (en) | 2020-01-28 |
EP3196194A4 (en) | 2018-05-30 |
AU2015317937B2 (en) | 2018-10-04 |
KR20170048593A (en) | 2017-05-08 |
TW201612165A (en) | 2016-04-01 |
LT3196194T (en) | 2019-10-10 |
CY1122423T1 (en) | 2021-01-27 |
CA2982881A1 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017112299A (en) | METHOD FOR PRODUCING AROMATIC HETEROCYCLIC COMPOUND USED AS JAK1 SELECTIVE KINASE INHIBITOR AND USING AROMATIC HETEROCYCLIC COMPOUND | |
US10300060B2 (en) | Trk-inhibiting compound | |
RU2621732C2 (en) | Substituted pyrimidinyl pyrroles active as kinase inhibitors | |
AU2015331166B2 (en) | Compounds and compositions for modulating EGFR mutant kinase activities | |
CA2545427C (en) | Selective kinase inhibitors | |
RU2625799C2 (en) | Tienopyrimydine [3,2-d] production, which has inhibitory activity against protein kinases | |
DK2643313T3 (en) | Quinazolincarboxamidazetidiner | |
JP2017502940A5 (en) | ||
JP2013528204A5 (en) | ||
WO2012139930A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
JP2008517926A5 (en) | ||
CA2687265A1 (en) | P70 s6 kinase inhibitors | |
WO2013066833A1 (en) | Compounds and methods to inhibit histone deacetylase (hdac) enzymes | |
KR20070066988A (en) | Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical compostion containing same | |
ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
RU2009119181A (en) | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS Glycogen synthase-kinase-3 inhibitors | |
RU2005132632A (en) | NUCLEOSIDE INHIBITORS OF I REVERSE TRANSCRIPTASE INTENDED FOR TREATMENT OF HIV DISEASES MEDIATED | |
RU2013132930A (en) | Pyrazole derivative | |
RU2013141559A (en) | METHOD FOR INHIBITING HAMARTOMA TUMOR CELL CELLS | |
Nemeth et al. | Novel, selective CDK9 inhibitors for the treatment of HIV infection | |
JP2015502371A5 (en) | ||
JP2015524825A5 (en) | ||
ES2556235T3 (en) | 2,5-disubstituted arylsulfonamides CCR3 antagonists | |
JP2015522607A5 (en) | ||
JP2014520108A5 (en) |